Pemtutamide
Pemtutamide (GLP-1/GIP/Glucagon Triple Agonist)
Overview
Pemtutamide is an investigational triple receptor agonist targeting GLP-1 GIP and glucagon receptors developed by Pfizer for the treatment of obesity and type 2 diabetes. It represents one of several next-generation multi-agonist metabolic peptides following the commercial success of semaglutide and tirzepatide. Early clinical data suggests significant weight loss efficacy with the triple agonism approach potentially offering differentiated metabolic benefits through the glucagon receptor component.
Mechanism of Action
Pemtutamide simultaneously activates GLP-1 receptors (incretin effect appetite suppression gastric emptying delay) GIP receptors (complementary incretin and adipose tissue effects) and glucagon receptors (hepatic fat oxidation thermogenesis increased energy expenditure). The triple agonism approach aims to maximize weight loss by targeting all three major receptor systems involved in energy homeostasis simultaneously. The glucagon component differentiates this class from pure GLP-1 agonists by adding a direct energy expenditure component rather than relying solely on reduced caloric intake.
Dosage Information
Typical Dose
Phase 1/2 trial doses being established
Frequency
Once weekly (anticipated)
Administration
Subcutaneous injection
Notes
Early clinical stage compound. Entry documents research context. Not yet approved for clinical use.
Where does Pemtutamide sit?
See how this peptide compares across all 111 peptides in our database.
Evidence Score
0.26
Potential Side Effects
Community Experiences
No experiences shared yet. Be the first!
Quick Facts
- Administration
- Subcutaneous injection
- Typical Dose
- Phase 1/2 trial doses being established
- Frequency
- Once weekly (anticipated)
- References
- 0 curated + 17 from PubMed
- Evidence Score
- 0.3 / 100